What's New
News
Family Caregivers’ Unique Support Needs
Partners in FTD Care Winter 2019 An FTD diagnosis presents families with an overwhelming and ever-changing list…
Financial Safety and Anosognosia
Partners in FTD Care Winter 2019 Financial supervision early in FTD care is extremely important, particularly when…
What to Do About… Anosognosia
Partners in FTD Care Winter 2019 Anosognosia is a lack of awareness of one’s own condition and…
Everything Is Just Fine: Anosognosia in Frontotemporal Degeneration
Partners in FTD Care, Winter 2019 Download the full issue (pdf) Caring for people with FTD presents…
Spread the Love with AFTD’s With Love Campaign 2019
Valentine’s Day is just around the corner – and with it comes the return of AFTD’s annual…
NY Post Highlights Book by Former FTD Care Partner
An article published in the New York Post on January 22 chronicles one woman’s journey as an…
AFTD Invests $2.5 Million in ADDF’s Diagnostics Accelerator Program to Develop FTD Biomarkers
Leveraging generous support from our donors, AFTD’s FTD Biomarkers Initiative is expanding. We are investing $2.5MM in…
“Sharing Hope” — AFTD’s 2018 Annual Report
AFTD’s 2018 Annual Report documents progress made in the fiscal year commencing July 1, 2017 and ending…
FTD and AFTD Now Included in Federal Research Portfolio
AFTD has been added to the International Alzheimer’s and Related Dementias Research Portfolio (IADRP), an online database…
Alector Receives Orphan Drug Designation for FTD Therapy
In August, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Alector for the…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)